In an attempt to decrease toxicity in high-risk patients undergoing unrelated donor
hematopoietic stem cell transplantation (URD HSCT), we tested a combination of …

In this open single-centre phase II study, MMF was added on day+ 10 after allogeneic
transplantation to standard immunosuppressive prophylaxis consisting of cyclosporine and …

We report the results of HLA-matched unrelated donor allogeneic stem cell transplantation
with new GVHD prophylaxis regimen consisted of cyclosporine, methotrexate and low-dose …

Graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide
(CY) after ablative HLA-matched bone marrow (BM) transplantation has been reported to …

Acute GVHD is a major contributor to morbidity and mortality following NST. A high
incidence of grades II–IV GVHD occurs when cyclosporine A (CSA) alone is used as …

GVHD is a major cause of mortality following unrelated donor (URD) hematopoietic cell
transplantation. As standard regimens using CYA or tacrolimus in combination with MTX are …

We evaluated tacrolimus/mycophenolate mofetil (MMF) for graft-versus-host disease
(GVHD) prophylaxis after a nonmyeloablative stem cell transplantation (NST) from a …

The use of reduced intensity conditioning (RIC) regimens for allogeneic stem cell
transplantation (allo-SCT) can result in a significant decrease in early procedure-related …

We evaluated the efficacy of a post-grafting immunosuppressive regimen consisting of
tacrolimus, methotrexate, and mycophenolate mofetil (MMF) in 21 adults (median age, 55 …

The association of Cyclosporine A (CsA) and mycophenolate mofetil (MMF) has increased in
the setting of reduced intensity conditioning (RIC). Nevertheless, the use of CsA or CsA+ …